Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting
Go back to Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-ALS to be Presented at the American Neurological Association Annual Meeting| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 228.69 +1.09 (0.48%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $227.60 | 52 Week High | $333.65 | |||
| Open | $225.87 | 52 Week Low | $223.02 | |||
| Day High | $230.49 | P/E | 29.28 | |||
| Day Low | $225.51 | EPS | $7.81 | |||
| Volume | 1,332,336 | |||||
| (NASDAQ: IONS) | Delayed: 45.57 +1.07 (2.40%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.50 | 52 Week High | $62.68 | |||
| Open | $44.56 | 52 Week Low | $19.59 | |||
| Day High | $46.95 | P/E | N/A | |||
| Day Low | $44.06 | EPS | $0.00 | |||
| Volume | 3,742,298 | |||||
